Delving into the Latest Updates on TDI-01 with Synapse

1. Ib期研究阶段主要目的：评价TDI01混悬液治疗既往至少经过1线不超过5线系统治疗的中重度cGVHD患者的有效性和安全性。次要目的：评价TDI01混悬液治疗既往至少经过1线不超过5线系统治疗的中重度cGVHD患者的群体药代动力学特征。 2. II期研究阶段主要目的：评价TDI01混悬液治疗既往至少经过1线不超过5线系统治疗的中重度cGVHD患者的有效性。次要目的：评价TDI01混悬液治疗既往至少经过1线不超过5线系统治疗的中重度cGVHD患者的安全性以及群体药代动力学特征。

[Translation]

1. Phase Ib study Primary objective: To evaluate the efficacy and safety of TDI01 suspension in the treatment of patients with moderate to severe cGVHD who have received at least 1 line but no more than 5 lines of systemic treatment. Secondary objective: To evaluate the population pharmacokinetic characteristics of TDI01 suspension in the treatment of patients with moderate to severe cGVHD who have received at least 1 line but no more than 5 lines of systemic treatment. 2. Phase II study Primary objective: To evaluate the efficacy of TDI01 suspension in the treatment of patients with moderate to severe cGVHD who have received at least 1 line but no more than 5 lines of systemic treatment. Secondary objective: To evaluate the safety and population pharmacokinetic characteristics of TDI01 suspension in the treatment of patients with moderate to severe cGVHD who have received at least 1 line but no more than 5 lines of systemic treatment.

Start Date06 Feb 2024

Sponsor / Collaborator

Beijing Tide Pharmaceutical Co., Ltd.

100 Clinical Results associated with TDI-01

Login to view more data

100 Translational Medicine associated with TDI-01

Login to view more data

100 Patents (Medical) associated with TDI-01

Login to view more data

3

Literatures (Medical) associated with TDI-01

01 Jan 2023·Frontiers in immunology

Deficiency of endothelial FGFR1 signaling via upregulation of ROCK2 activity aggravated ALI/ARDS.

Article

Author: Hu, Yan ; Deng, Yue ; Huang, Xingming ; Zhong, Weiting ; Wang, Hongjun ; Wang, Chen ; Zhang, Hua ; Ding, Bi-Sen ; Mo, Chunheng

Vascular leakage and inflammation are pathological hallmarks of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Endothelial cells (ECs) serve as a semipermeable barrier and play a key role in disease progression. It is well known that fibroblast growth factor receptor 1 (FGFR1) is required for maintaining vascular integrity. However, how endothelial FGFR1 functions in ALI/ARDS remains obscure. Here, we revealed that conditional deletion of endothelial FGFR1 aggravated LPS-induced lung injury, including inflammation and vascular leakage. Inhibition of its downstream Rho-associated coiled-coil-forming protein kinase 2 (ROCK2) by AAV Vec-tie-shROCK2 or its selective inhibitor TDI01 effectively attenuated inflammation and vascular leakage in a mouse model. In vitro, TNFα-stimulated human umbilical vein endothelial cells (HUVECs) showed decreased FGFR1 expression and increased ROCK2 activity. Furthermore, knockdown of FGFR1 activated ROCK2 and thus promoted higher adhesive properties to inflammatory cells and higher permeability in HUVECs. TDI01 effectively suppressed ROCK2 activity and rescued the endothelial dysfunction. These data demonstrated that the loss of endothelial FGFR1 signaling mediated an increase in ROCK2 activity, which led to an inflammatory response and vascular leakage in vivo and in vitro. Moreover, inhibition of ROCK2 activity by TDI01 provided great value and shed light on clinical translation.

01 Dec 1997·ToxiconQ3 · MEDICINE

Isolation and characterization of a potent curarizing polypeptide from Tityus discrepans scorpion venom

Q3 · MEDICINE

Article

Author: James W. Fox ; J. F. Pérez ; C. Sevcik ; G. D'Suze

The pure TdI-1 polypeptide that blocks miniature endplate potentials (MEPPs) and abolishes or reduces endplate potentials (EPPs) below the action potential threshold was identified from the crude fraction of Tityus discrepans venom. The toxin is a potent reversible non-depolarizing muscle relaxant that blocks more than 95% of the EPP at a 2 microM (0.1 mg/ml) concentration. On a molar basis, TdI-1 is as potent as or more potent than many muscle relaxants since, at the concentration used, the toxin suppressed more than 95% of the EPP. Using matrix-assisted laser desorption time of flight (MALD-TOF) ionization mass spectrometry, TdI-1 was found to have an unusally large mol. wt for a scorpion toxin, close to 48,000. The N-terminal sequence of the first 23 residues of TdI-1 was also determined. The fragment differs from the N-terminal sequences of all 140 peptidic scorpion toxins found in the SWISSPROT and PIR databases using the search engine of the felix.EMBL-Heidelberg.de computer (European Molecular Biology Laboratory, Heidelberg, Germany.

01 Jul 1990·Avian PathologyQ2 · AGRICULTURAL & FORESTRY SCIENCE

Studies with a bivalent infectious bronchitis killed virus vaccine

Q2 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Box, P G ; Finney, P M ; Holmes, H C

Haemagglutination inhibition and virus neutralisation antibody responses of chickens given different vaccination programmes were compared. This was followed by a further experiment in which variously vaccinated laying hens were challenged at 30 weeks of age with two strains of infectious bronchitis virus of the "variant" Dutch D207 serotype. Chickens were given primary vaccinations to different strains of infectious bronchitis live virus during rearing and then injected at 16 weeks of age with inactivated oil adjuvanted virus vaccines prepared from either M41, GV101 or both viruses combined (bivalent vaccine). Antibody titres to M41 infectious bronchitis virus were high, and to D207 serotype low. in birds given Mass type vaccines only. In birds given an initial 'priming' with Mass type live vaccine and then 'boosted' with bivalent killed vaccine, high haemagglutination inhibition and virus neutralisation antibody levels against both the M41 and D207 serotypes of infectious bronchitis virus were stimulated. In another experiment, the ability of laying hens vaccinated according to this programme, to withstand challenge with two strains of virulent infectious bronchitis virus of the D207 serotype, was tested. Protection of egg production in vaccinated hens was found to be good and in all groups correlated with the individual hen haemagglutination inhibition titre at the time of challenge. The significance of these results with regard to the use of killed virus vaccines in laying hens and to the necessity to develop live virus vaccines from 'variant' strains of infectious bronchitis virus is discussed.

100 Deals associated with TDI-01

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic graft-versus-host disease	Phase 2	CN	Beijing Tide Pharmaceutical Co., Ltd.	06 Feb 2024
Idiopathic Pulmonary Fibrosis	Phase 2	-	Beijing Tide Pharmaceutical Co., Ltd.	02 Nov 2023
COVID-19	Phase 2	CN	Beijing Tide Pharmaceutical Co., Ltd.	-
COVID-19	Phase 2	US	Beijing Tide Pharmaceutical Co., Ltd.	-
Neoplasms	Phase 1	CN	Beijing Tide Pharmaceutical Co., Ltd.	23 Feb 2021
Central Nervous System Diseases	Phase 1	CN	Beijing Tide Pharmaceutical Co., Ltd.	-
Pneumoconiosis	Phase 1	CN	Beijing Tide Pharmaceutical Co., Ltd.	-
Pneumoconiosis	Phase 1	US	Beijing Tide Pharmaceutical Co., Ltd.	-
Fibrosis, Liver	IND Approval	CN	Beijing Tide Pharmaceutical Co., Ltd.	20 Sep 2024